TABLE 7.
Comparison of genotype-specific signal strengths,a measured by the Onclarity assay, on self-taken samples and physician-taken follow-up samplesb
| HPV genotype | Median (IQR) CT for samples with the following resultsc: |
|||
|---|---|---|---|---|
| Brush positive, physician negative (n = 165) |
Brush positive, physician positive (n = 339) |
|||
| Self-taken samples | Physician-taken samples | Self-taken samples | Physician-taken samples | |
| HPV16 | 32.47 (30.27–33.29) | Negative | 26.47 (23.49–29.99) | 25.34 (22.49–30.19) |
| HPV18 | 30.57 (28.45–31.88) | Negative | 27.46 (23.85–29.81) | 27.90 (23.95–29.81) |
| HPV31 | 30.66 (27.67–31.94) | Negative | 25.85 (22.65–30.30) | 26.65 (23.18–29.65) |
| HPV33/58 | 28.11 (26.93–31.23) | Negative | 28.26 (24.74–30.61) | 26.76 (24.04–29.92) |
| HPV35/39/68 | 30.65 (25.40–31.72) | Negative | 26.44 (24.87–30.46) | 27.14 (24.71–30.70) |
| HPV45 | 29.55 (27.59–32.90) | Negative | 27.33 (23.66–31.56) | 29.88 (25.69–31.88) |
| HPV51 | 30.45 (26.76–32.84) | Negative | 25.75 (22.79–30.18) | 28.45 (24.96–32.84) |
| HPV52 | 30.00 (28.96–31.34) | Negative | 26.04 (22.02–28.73) | 26.31 (18.97–30.81) |
| HPV56/59/66 | 30.75 (28.81–32.66) | Negative | 26.04 (21.73–29.52) | 27.21 (23.59–30.44) |
a
Expressed as the cycle threshold (CT). The cutoff was a CT value of 34.2.
b
In total, of the 532 women with HPV infections detected by the Onclarity assay on the self-taken sample who had follow-up physician testing, 504 (95%) had a valid Onclarity test result on the physician sample.
c
IQR, interquartile range. “Brush positive,” HPV-positive test results for self-taken samples; “physician negative,” HPV-negative test results for physician-taken follow-up samples.